As I recall, Dr. Missling said that recognition of the S1-r is at an all-time high right now because the medical establishment is finally waking up to its MOA.
This is exactly what you want to see when you're invested in a biotech company that is 10 years ahead of everyone else.
I see tremendous growth ahead for Anavex's two main drugs...A2-73 and 3-71.